Circulating CD34+, CD133+, and vascular endothelial growth factor receptor 2-positive endothelial progenitor cells in myelofibrosis with myeloid metaplasia

被引:67
作者
Massa, M
Rosti, V
Ramajoli, I
Campanelli, R
Pecci, A
Viarengo, G
Meli, V
Marchetti, M
Hoffman, R
Barosi, G
机构
[1] IRCCS, Policlin San Matteo, Lab Epidemiol Clin, I-27100 Pavia, Italy
[2] IRCCS, Policlin San Matteo, Biotechnol Lab, Lab Clin Epidemiol, I-27100 Pavia, Italy
[3] IRCCS, Policlin San Matteo, Transplant Res Area, Lab Clin Epidemiol, I-27100 Pavia, Italy
[4] IRCCS, Policlin San Matteo, Unit Internal Med 3, Lab Clin Epidemiol, I-27100 Pavia, Italy
[5] IRCCS, Policlin San Matteo, Unit Clin Immunol Immunohematol & Transfus Serv, Lab Clin Epidemiol, I-27100 Pavia, Italy
[6] IRCCS, Policlin San Matteo, Dept Pediat, Lab Clin Epidemiol, I-27100 Pavia, Italy
[7] Univ Illinois, Ctr Canc, Hematol Oncol Sect, Dept Pathol,Coll Med, Chicago, IL 60680 USA
[8] Myeloproliferat Disorders Res Consortium, Chicago, IL USA
关键词
D O I
10.1200/JCO.2005.09.021
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Endothelial progenitor cells (EPCs) are present in circulation and contribute to vasculogenesis in adults, We measured the number of circulating EPCs in patients with myelofibrosis with myeloid metaplasia (MMM), and we examined the relationship between the number of EPCs and severity of the MMM disease process. Patients and Methods The number of EPCs was measured by assaying the CD34(+)CD133(+) vascular endothelial growth factor receptor 2 (VEGFB2)-positive cell phenotype in 110 MMM patients, 16 patients with other Philadelphia-negative chronic myeloproliferative disorders (Ph-negative CMPDs), and 14 healthy participants. In four MMM patients, the capacity of selected CD34(+) cells to form endothelial colonies (CFU-End) in vitro was tested. Results CD34(+), CD133(+), and VEGFR2-positive EPCs were detectable in unselected peripheral-blood cells of 50.9% MMM patients, 37.5% control patients, and 21% healthy participants. Patients with MMM had a median of 0.26% EPCs, significantly higher than that in healthy controls (median, 0%) and in patients with other Ph-negative CMPDs (median, 0.1%). In 14.5% of MMM patients, the numbers of EPCs were greater than the highest value found in patients with other Ph-negative CMPDs. CD34(+) selected cells produced colony-forming unit-endothelial (CFU-End), which were vascular endothelial (VE) -cadherin positive, CD31(+), von Willebrand factor positive, and CD45(-). In MMM patients, the larger the number of EPCs, the smaller the number of circulating immature myeloid cells and circulating CD45(+)CD34(+) hematopoietic progenitor cells. Increased numbers of EPCs were associated with younger age and a diagnosis of prefibrotic MMM. Conclusion Circulating EPICS are elevated in MMM patients in the early stage of the disease. Heightened mobilization of EPCs may represent an important mechanism for development of neoangiogenesis in MMM.
引用
收藏
页码:5688 / 5695
页数:8
相关论文
共 35 条
[1]   Increase of circulating endothelial progenitor cells in patients with coronary artery disease after exercise-induced ischemia [J].
Adams, V ;
Lenk, K ;
Linke, A ;
Lenz, D ;
Erbs, S ;
Sandri, M ;
Tarnok, A ;
Gielen, S ;
Emmrich, F ;
Schuler, G ;
Hambrecht, R .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2004, 24 (04) :684-690
[2]   Assessment of the tissue distribution of transplanted human endothelial progenitor cells by radioactive labeling [J].
Aicher, A ;
Brenner, W ;
Zuhayra, M ;
Badorff, C ;
Massoudi, S ;
Assmus, B ;
Eckey, T ;
Henze, E ;
Zeiher, AM ;
Dimmeler, S .
CIRCULATION, 2003, 107 (16) :2134-2139
[3]   Isolation of putative progenitor endothelial cells for angiogenesis [J].
Asahara, T ;
Murohara, T ;
Sullivan, A ;
Silver, M ;
vanderZee, R ;
Li, T ;
Witzenbichler, B ;
Schatteman, G ;
Isner, JM .
SCIENCE, 1997, 275 (5302) :964-967
[4]   Myelofibrosis with myeloid metaplasia: Diagnostic definition and prognostic classification for clinical studies and treatment guidelines [J].
Barosi, G .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (09) :2954-2970
[5]   The Italian consensus conference on diagnostic criteria for myelofibrosis with myeloid metaplasia [J].
Barosi, G ;
Ambrosetti, A ;
Finelli, C ;
Grossi, A ;
Leoni, P ;
Liberato, NL ;
Petti, MC ;
Pogliani, E ;
Ricetti, M ;
Rupoli, S ;
Visani, G ;
Tura, S .
BRITISH JOURNAL OF HAEMATOLOGY, 1999, 104 (04) :730-737
[6]   Spleen neoangiogenesis in patients with myelofibrosis with myeloid metaplasia [J].
Barosi, G ;
Vittorio, R ;
Margherita, MS ;
Luca, VG ;
Alessandro, P ;
Vittorio, N ;
Isabella, R ;
Rita, C ;
Monia, M ;
Mario, B ;
Is, MNAEH .
BRITISH JOURNAL OF HAEMATOLOGY, 2004, 124 (05) :618-625
[7]   A PROGNOSTIC CLASSIFICATION OF MYELOFIBROSIS WITH MYELOID METAPLASIA [J].
BAROSI, G ;
BERZUINI, C ;
LIBERATO, LN ;
COSTA, A ;
POLINO, G ;
ASCARI, E .
BRITISH JOURNAL OF HAEMATOLOGY, 1988, 70 (04) :397-401
[8]   Diagnostic and clinical relevance of the number of circulating CD34+ cells in myelofibrosis with myeloid metaplasia [J].
Barosi, G ;
Viarengo, G ;
Pecci, A ;
Rosti, V ;
Piaggio, G ;
Marchetti, M ;
Frassoni, F .
BLOOD, 2001, 98 (12) :3249-3255
[9]  
BERLIN NI, 1975, SEMIN HEMATOL, V12, P339
[10]   Myelofibrosis with myeloid metaplasia in young individuals: disease characteristics, prognostic factors and identification of risk groups [J].
Cervantes, F ;
Barosi, G ;
Demory, JL ;
Reilly, J ;
Guarnone, R ;
Dupriez, B ;
Pereira, A ;
Montserrat, E .
BRITISH JOURNAL OF HAEMATOLOGY, 1998, 102 (03) :684-690